Tarsus Pharmaceuticals, Inc. TARS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 10:25 AM EDT
28.34quote price arrow down-0.26 (-0.93%)
Volume
7,551
52 week range
15.32 - 63.69

...

Loading . . .
  • Open28.71
  • Day High28.85
  • Day Low28.34
  • Prev Close28.61
  • 52 Week High63.69
  • 52 Week High Date12/18/20
  • 52 Week Low15.32
  • 52 Week Low Date10/16/20

Key Stats

  • Market Cap581.07M
  • Shares Out20.50M
  • 10 Day Average Volume0.04M
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-30.86

KEY STATS

  • Open28.71
  • Day High28.85
  • Day Low28.34
  • Prev Close28.61
  • 52 Week High63.69
  • 52 Week High Date12/18/20
  • 52 Week Low15.32
  • 52 Week Low Date10/16/20
  • Market Cap581.07M
  • Shares Out20.50M
  • 10 Day Average Volume0.04M
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-30.86

RATIOS/PROFITABILITY

  • EPS (TTM)-1.31
  • P/E (TTM)-21.68
  • Fwd P/E (NTM)-10.86
  • EBITDA (MRQ)-26.899M
  • ROE (MRQ)-
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest From Tarsus Pharmaceuticals, Inc.

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
Tarsus Pharmaceuticals Inc. is a late clinical-stage biopharmaceutical company. The Company if focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. Its lead product candidate, TP-03, is a novel therapeutic being developed for the treatment of blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). It is developing TP-03 as an eye drop. It is also focused on developing additional clinical-stage...
Address
15440 Laguna Canyon Road
Irvine, CA
92618
United States